<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03191175</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2016/14</org_study_id>
    <nct_id>NCT03191175</nct_id>
  </id_info>
  <brief_title>Inflammasome Activation Via Circulating Metabolites</brief_title>
  <acronym>InflammoVIH</acronym>
  <official_title>Residual Immune Activation in HIV-infected Patients on Successful cART: Association Between Inflammasome Activation in Monocytes by Circulating Metabolites and Non AIDS Defining Comorbidities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sidaction</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre National de la Recherche Scientifique, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical challenges confronting patients with HIV has shifted over the past 10 years from
      acquired immunodeficiency syndrome to chronic diseases including atherosclerosis,
      neurocognitive disorders, and osteoporosis. Chronic low grade inflammation and monocyte
      activation have been consistently associated with comorbidities in HIV patients. Indeed,
      recent studies indicate that inflammatory mediators including IL-6, IL-1, sCD14 and s CD163
      produced by monocytes, but not T-cell activation, predict Non-AIDS-related events in
      virologically suppressed HIV-infected persons treated with combined antiretroviral therapy
      (cART), highlighting the important role of monocyte activation in the occurrence of
      comorbidities in cART-treated HIV infected patients. Yet, the underlying molecular pathways
      of persistent monocyte activation in cART treated HIV-infected patients remains incompletely
      characterized. Our preliminary results: 1/ establish a link between the activation of the
      inflammasome, the increased of pyrimidine-derived metabolites and the cardiovascular risk in
      a cohort of elderly patients; 2/ show that treated HIV-patients are characterized by
      increased soluble IL-1b or IL-18 in their blood suggesting that the inflammasome pathway is
      activated.

      Objectives: In this study we will characterize the molecular pathways underlying persistent
      monocyte activation in treated HIV patients, through the implication of the activation of the
      inflammasome machinery: 1. Characterization of NOD like Receptor (NLR) expression in
      monocytes for IL-1b and IL-18 secretion (inflammasome activation); 2. Characterization of
      circulating metabolites that active the inflammasome machinery; 3. Evaluation of the link
      between the activation of the inflammasome, the increased of circulating metabolites and the
      non-AIDS related comorbidities.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2017</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characterization of NLR (s) implicated in IL-18 up-regulation (inflammasome activation) in HIV</measure>
    <time_frame>At baseline (D0)</time_frame>
    <description>The metabolic profile in purified monocytes from HIV patients through label-free proteomics and assignment of metabolic targets
The expression of NLR genes by quantitative Polymerase Chain Reaction (qPCR) in purified monocytes from HIV patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Characterization of circulating metabolites that active the inflammasome machinery</measure>
    <time_frame>At baseline (D0)</time_frame>
    <description>analysis of the ability of sera from HIV patients to activate inflammasome in HIV negative monocytes, and to induce IL-1, IL-18, or both secretion.
metabolomic profile
analysis of the ability of predominant metabolites in HIV patients to activate inflammasome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-AIDS related comorbidities</measure>
    <time_frame>At baseline (D0)</time_frame>
    <description>metabolites of interest, inflammasome activation measured by IL-1b and IL-18</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>HIV patients</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>47ml blood (40 ml EDTA whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation and 7 ml for serum).</description>
    <arm_group_label>HIV patients</arm_group_label>
    <arm_group_label>Control patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood sampling
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected patients with long-term suppressed viral load on cART
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        HIV patients :

        Inclusion Criteria:

          -  Aged 18 years and above

          -  HIV-1 infected patients

          -  Enrolled in the CIADIS substudy of the ANRS CO3 Aquitaine cohort

          -  Patients receiving antiretroviral therapy

          -  HIV-1 RNA load below the detection limit of 40 copies/mL

          -  With a written and signed informed consent

        Exclusion Criteria:

          -  HIV-2 or HIV-1/HIV-2 co-infection

        Control patients :

        Inclusion Criteria:

          -  Aged 18 years and above

        Exclusion Criteria:

          -  HIV-1, HIV-2 or HIV-1/HIV-2 infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda WITTKOP, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Université de Bordeaux - ISPED - Inserm 2129 - CHU de Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Isabelle PELLEGRIN, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bordeaux</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Benjamin FAUSTIN, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centre National de la Recherche Scientifique, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isabelle PELLEGRIN, MD, PhD</last_name>
    <phone>(0)5 57 82 11 50</phone>
    <phone_ext>+33</phone_ext>
    <email>isabelle.pellegrin@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Olivier LELEUX</last_name>
    <phone>(0)5 57 57 45 44</phone>
    <phone_ext>+33</phone_ext>
    <email>olivier.leleux@u-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'immunologie</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle PELLEGRIN, MD</last_name>
      <email>isabelle.pellegrin@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Olivier LELEUX</last_name>
      <email>olivier.leleux@u-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Isabelle PELLEGRIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean-François VIALLARD, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabrice BONNET, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Didier NEAU, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel DUPON, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick MERCIE, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Furman D, Chang J, Lartigue L, Bolen CR, Haddad F, Gaudilliere B, Ganio EA, Fragiadakis GK, Spitzer MH, Douchet I, Daburon S, Moreau JF, Nolan GP, Blanco P, Déchanet-Merville J, Dekker CL, Jojic V, Kuo CJ, Davis MM, Faustin B. Expression of specific inflammasome gene modules stratifies older individuals into two extreme clinical and immunological states. Nat Med. 2017 Feb;23(2):174-184. doi: 10.1038/nm.4267. Epub 2017 Jan 16.</citation>
    <PMID>28092664</PMID>
  </reference>
  <reference>
    <citation>Ozanne A, Duffau P, Dauchy FA, Rigothier C, Terrien C, Lazaro E, Cazanave C, Lawson-Ayayi S, Bonnet F, Blanco P, Wittkop L, Pellegrin I; CIADIS sub-study in the ANRS CO3 Aquitaine cohort study group. Activation, senescence and inflammation markers in HIV patients: association with renal function. AIDS. 2017 May 15;31(8):1119-1128. doi: 10.1097/QAD.0000000000001461.</citation>
    <PMID>28328797</PMID>
  </reference>
  <reference>
    <citation>Duffau P, Wittkop L, Lazaro E, le Marec F, Cognet C, Blanco P, Moreau JF, Dauchy FA, Cazanave C, Vandenhende MA, Bonnet F, Thiebaut R, Pellegrin I; ANRS CO3 Aquitaine Cohort Study Group. Association of immune-activation and senescence markers with non-AIDS-defining comorbidities in HIV-suppressed patients. AIDS. 2015 Oct 23;29(16):2099-108. doi: 10.1097/QAD.0000000000000807.</citation>
    <PMID>26544576</PMID>
  </reference>
  <reference>
    <citation>Wittkop L, Bitard J, Lazaro E, Neau D, Bonnet F, Mercie P, Dupon M, Hessamfar M, Ventura M, Malvy D, Dabis F, Pellegrin JL, Moreau JF, Thiébaut R, Pellegrin I; Groupe d'Epidémiologie Clinique du SIDA en Aquitaine. Effect of cytomegalovirus-induced immune response, self antigen-induced immune response, and microbial translocation on chronic immune activation in successfully treated HIV type 1-infected patients: the ANRS CO3 Aquitaine Cohort. J Infect Dis. 2013 Feb 15;207(4):622-7. doi: 10.1093/infdis/jis732. Epub 2012 Nov 29.</citation>
    <PMID>23204178</PMID>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 14, 2017</study_first_submitted>
  <study_first_submitted_qc>June 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 19, 2017</study_first_posted>
  <last_update_submitted>July 6, 2017</last_update_submitted>
  <last_update_submitted_qc>July 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Inflammasome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

